Genotype-related Effects of PUFA
Not Applicable
Completed
- Conditions
- Healthy
- Interventions
- Dietary Supplement: Triple Strength Fish Oil
- Registration Number
- NCT02296385
- Lead Sponsor
- Société des Produits Nestlé (SPN)
- Brief Summary
To assess the bioefficacy of omega-3 fatty acids (provided by intake of fish oil supplements) depending on genotype of relevant factors in lipid metabolism
- Detailed Description
To assess the bioefficacy of omega-3 fatty acids (provided by intake of fish oil supplements) depending on genotype of relevant factors in lipid metabolism.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 200
Inclusion Criteria
- Healthy adult between 18 and 40 years of age
- BMI between 18.5 and 30 kg/m2
- Sedentary to moderate physical activity habits
Exclusion Criteria
- Concomitant treatment: Consumption of dietary supplements or any medication that can affect the study outcomes
- Actively smoking
- Suspected abuse of alcohol or illicit drugs
- Significant illness within the two weeks prior to study start or any active systemic infection or medical condition that may require treatment during the study
- Known or suspected medical condition related to coagulation
- Subject who cannot be expected to comply with the study procedures
- Currently participating or having participated in another clinical trial during the last 4 weeks prior to beginning of this study
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description Supplementation Triple Strength Fish Oil Supplementation
- Primary Outcome Measures
Name Time Method Changes in triglyceride levels in plasma Baseline and 6 weeks intervention
- Secondary Outcome Measures
Name Time Method Assess bioefficacy of EPA and DHA supplementation Baseline and 6 weeks intervention The bioefficacy will be evaluated by characterizing and measuring the effects on lipid metabolism, glucose metabolism and insulin resistance, and inflammatory response